Handelsavisen
prelaunch
Companies ›Healthcare ›464490.KQ
46
464490.KQ — KOSDAQ Biotechnology & Medical Research

464490.Kq

$10 890,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-59,7 %
ROE
-22,5 %
Net margin
-64,8 %
Debt / equity
0,24
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the healthcare diagnostics segment, providing products and services related to medical research and diagnostic tools.

Business. The company operates in the healthcare diagnostics segment, providing products and services related to medical research and diagnostic tools.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-22,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 464490.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 464490.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, providing products and services related to medical research and diagnostic tools.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 26.5 billion, representing a significant portion of its total assets of KRW 51.2 billion. The liquidity FPT (free cash flow to total assets) is negative, indicating a cash outflow from operations, with a free cash flow of KRW -6.05 billion. The current ratio of 2.87 suggests the company has sufficient short-term assets to cover its short-term liabilities.

    Profitability metrics show a challenging financial position, with a return on equity of -22.5% and a return on assets of -13.54%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income is negative at KRW -6.38 billion, and the net income is also negative at KRW -6.93 billion, reflecting ongoing operational losses.

    The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot. There is no geographic breakdown provided, but the company's operations are likely centered in its home market. The lack of geographic diversification may expose the company to regional economic or regulatory risks.

    The company's growth trajectory is currently negative, with a net income decline and a free cash flow outflow. The operating cash flow is also negative at KRW -4.55 billion, indicating that the company is not generating sufficient cash from its operations to sustain its activities. The capital expenditure of KRW -2.42 billion suggests ongoing investment in infrastructure or expansion, but this is not offsetting the operational cash outflows.

    Risk factors include a low liquidity risk, as the company has a substantial cash reserve. However, the negative free cash flow and operating cash flow indicate potential future liquidity constraints. The dilution risk is low, with no immediate filing-based flags detected. The company has not issued additional shares recently, and the number of shares outstanding remains stable.

    Recent events include the latest financial filing, which shows a continued decline in profitability and cash flow. There are no recent transcripts or other disclosures indicating significant strategic changes or new product launches. The company's financial performance remains a key area of focus for investors and analysts.

    Key takeaways
    • The company has a strong liquidity position with significant cash reserves but is experiencing negative free cash flow and operating cash flow.
    • Profitability metrics are negative, with a return on equity of -22.5% and a return on assets of -13.54%.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • Growth is currently negative, with declining net income and free cash flow.
    • Liquidity risk is low, but the company's negative cash flows may pose future challenges.
    • There are no immediate dilution risks, and the company has not issued additional shares recently.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $10 890,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $30.80B
    Net cashⓘ
    $19.02B
    Current ratioⓘ
    2.9
    Debt / equityⓘ
    0.2
    ROAⓘ
    -13.5%
    ROEⓘ
    -22.5%
    Cash conversionⓘ
    66.0%
    CapEx / revenueⓘ
    -22.6%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-59,7 %Above median
    Net Margin-64,8 %Above median
    ROE-22,5 %Below median
    Capex / Rev-22,6 %Below median
    D/E0,24Bottom quartile
    Cash Conv0,66Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 464490.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    464490.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage